104 related articles for article (PubMed ID: 19796941)
1. Piperazinyl-glutamate-pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.
Parlow JJ; Burney MW; Case BL; Girard TJ; Hall KA; Hiebsch RR; Huff RM; Lachance RM; Mischke DA; Rapp SR; Woerndle RS; Ennis MD
Bioorg Med Chem Lett; 2009 Nov; 19(21):6148-56. PubMed ID: 19796941
[TBL] [Abstract][Full Text] [Related]
2. Part II: piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation.
Parlow JJ; Burney MW; Case BL; Girard TJ; Hall KA; Harris PK; Hiebsch RR; Huff RM; Lachance RM; Mischke DA; Rapp SR; Woerndle RS; Ennis MD
Bioorg Med Chem Lett; 2010 Feb; 20(4):1388-94. PubMed ID: 20097563
[TBL] [Abstract][Full Text] [Related]
3. Piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation.
Parlow JJ; Burney MW; Case BL; Girard TJ; Hall KA; Hiebsch RR; Huff RM; Lachance RM; Mischke DA; Rapp SR; Woerndle RS; Ennis MD
Bioorg Med Chem Lett; 2009 Aug; 19(16):4657-63. PubMed ID: 19604694
[TBL] [Abstract][Full Text] [Related]
4. Thienopyrimidine-based P2Y12 platelet aggregation inhibitors.
Kortum SW; Lachance RM; Schweitzer BA; Yalamanchili G; Rahman H; Ennis MD; Huff RM; TenBrink RE
Bioorg Med Chem Lett; 2009 Oct; 19(20):5919-23. PubMed ID: 19748783
[TBL] [Abstract][Full Text] [Related]
5. Piperazinyl glutamate pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation.
Parlow JJ; Burney MW; Case BL; Girard TJ; Hall KA; Harris PK; Hiebsch RR; Huff RM; Lachance RM; Mischke DA; Rapp SR; Woerndle RS; Ennis MD
J Med Chem; 2010 Mar; 53(5):2010-37. PubMed ID: 20141147
[TBL] [Abstract][Full Text] [Related]
6. Combined 3D-QSAR, molecular docking, and molecular dynamics study on piperazinyl-glutamate-pyridines/pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.
Hao M; Li Y; Wang Y; Yan Y; Zhang S; Li G; Yang L
J Chem Inf Model; 2011 Oct; 51(10):2560-72. PubMed ID: 21923153
[TBL] [Abstract][Full Text] [Related]
7. Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor.
Hasegawa M; Sugidachi A; Ogawa T; Isobe T; Jakubowski JA; Asai F
Thromb Haemost; 2005 Sep; 94(3):593-8. PubMed ID: 16268477
[TBL] [Abstract][Full Text] [Related]
8. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: potent and selective A(2A) adenosine antagonists.
Baraldi PG; Cacciari B; Spalluto G; Pineda de las Infantas y Villatoro MJ; Zocchi C; Dionisotti S; Ongini E
J Med Chem; 1996 Mar; 39(5):1164-71. PubMed ID: 8676354
[TBL] [Abstract][Full Text] [Related]
9. P2Y1 receptor antagonists as novel antithrombotic agents.
Pfefferkorn JA; Choi C; Winters T; Kennedy R; Chi L; Perrin LA; Lu G; Ping YW; McClanahan T; Schroeder R; Leininger MT; Geyer A; Schefzick S; Atherton J
Bioorg Med Chem Lett; 2008 Jun; 18(11):3338-43. PubMed ID: 18445527
[TBL] [Abstract][Full Text] [Related]
10. 6-Amino-2-mercapto-3H-pyrimidin-4-one derivatives as new candidates for the antagonism at the P2Y12 receptors.
Crepaldi P; Cacciari B; Bonache MC; Spalluto G; Varani K; Borea PA; Kügelgen Iv; Hoffmann K; Pugliano M; Razzari C; Cattaneo M
Bioorg Med Chem; 2009 Jul; 17(13):4612-21. PubMed ID: 19464902
[TBL] [Abstract][Full Text] [Related]
11. Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): pharmacodynamic and pharmacokinetic characterization.
Post JM; Alexander S; Wang YX; Vincelette J; Vergona R; Kent L; Bryant J; Sullivan ME; Dole WP; Morser J; Subramanyam B
Thromb Res; 2008; 122(4):533-40. PubMed ID: 18539312
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological activity of 5-aryl-4-(4-(5-methyl-1H-imidazol-4-yl)piperidin-1-yl)pyrimidine analogs as potent, highly selective, and orally bioavailable NHE-1 inhibitors.
Atwal KS; O'Neil SV; Ahmad S; Doweyko L; Kirby M; Dorso CR; Chandrasena G; Chen BC; Zhao R; Zahler R
Bioorg Med Chem Lett; 2006 Sep; 16(18):4796-9. PubMed ID: 16870436
[TBL] [Abstract][Full Text] [Related]
13. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
[TBL] [Abstract][Full Text] [Related]
14. Optimization of 2-phenyl-pyrimidine-4-carboxamides towards potent, orally bioavailable and selective P2Y(12) antagonists for inhibition of platelet aggregation.
Caroff E; Meyer E; Treiber A; Hilpert K; Riederer MA
Bioorg Med Chem Lett; 2014 Sep; 24(17):4323-31. PubMed ID: 25113932
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 2-chloro-N-((4,4-difluoro-1-hydroxycyclohexyl)methyl)-5-(5-fluoropyrimidin-2-yl)benzamide as a potent and CNS penetrable P2X7 receptor antagonist.
Chen X; Pierce B; Naing W; Grapperhaus ML; Phillion DP
Bioorg Med Chem Lett; 2010 May; 20(10):3107-11. PubMed ID: 20392639
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists.
Baraldi PG; Fruttarolo F; Tabrizi MA; Preti D; Romagnoli R; El-Kashef H; Moorman A; Varani K; Gessi S; Merighi S; Borea PA
J Med Chem; 2003 Mar; 46(7):1229-41. PubMed ID: 12646033
[TBL] [Abstract][Full Text] [Related]
17. Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I): in vitro effects on platelets.
Bryant J; Post JM; Alexander S; Wang YX; Kent L; Schirm S; Tseng JL; Subramanyam B; Buckman B; Islam I; Yuan S; Sullivan ME; Snider M; Morser J
Thromb Res; 2008; 122(4):523-32. PubMed ID: 18495218
[TBL] [Abstract][Full Text] [Related]
18. Substituted aryl pyrimidines as potent and soluble TRPV1 antagonists.
Stec MM; Bo Y; Chakrabarti PP; Liao L; Ncube M; Tamayo N; Tamir R; Gavva NR; Treanor JJ; Norman MH
Bioorg Med Chem Lett; 2008 Sep; 18(18):5118-22. PubMed ID: 18722118
[TBL] [Abstract][Full Text] [Related]
19. Cyclopenta[d]pyrimidines and dihydropyrrolo[2,3-d]pyrimidines as potent and selective corticotropin-releasing factor 1 receptor antagonists.
Arban R; Benedetti R; Bonanomi G; Capelli AM; Castiglioni E; Contini S; Degiorgis F; Di Felice P; Donati D; Fazzolari E; Gentile G; Marchionni C; Marchioro C; Messina F; Micheli F; Oliosi B; Pavone F; Pasquarello A; Perini B; Rinaldi M; Sabbatini FM; Vitulli G; Zarantonello P; Di Fabio R; St-Denis Y
ChemMedChem; 2007 Apr; 2(4):528-40. PubMed ID: 17335099
[TBL] [Abstract][Full Text] [Related]
20. Lipophilic modifications to dinucleoside polyphosphates and nucleotides that confer antagonist properties at the platelet P2Y12 receptor.
Douglass JG; Patel RI; Yerxa BR; Shaver SR; Watson PS; Bednarski K; Plourde R; Redick CC; Brubaker K; Jones AC; Boyer JL
J Med Chem; 2008 Feb; 51(4):1007-25. PubMed ID: 18232657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
